Nitric oxide nanoparticles: Pre-clinical utility as a therapeutic for intramuscular abscesses

David Schairer, Luis R. Martinez, Karin Blecher Paz, Jason Chouake, Parimala Nacharaju, Philip Gialanella, Joel M. Friedman, Joshua D. Nosanchuk, Adam Friedman

Research output: Contribution to journalArticlepeer-review

42 Scopus citations


Nitric oxide (NO) is a critical component of host defense against invading pathogens; however, its therapeutic utility is limited due to a lack of practical delivery systems. Recently, a NO-releasing nanoparticulate platform (NO-np) was shown to have in vitro broad-spectrum antimicrobial activity and in vivo pre-clinical efficacy in a dermal abscess model. To extend these findings, both topical (TP) and intralesional (IL) NO-np administration was evaluated in a MRSA intramuscular murine abscess model and compared with vancomycin. All treatment arms accelerated abscess clearance clinically, histologically, and by microbiological assays on both days 4 and 7 following infection. However, abscesses treated with NO-np via either route demonstrated a more substantial, statistically significant decrease in bacterial survival based on colony forming unit assays and histologically revealed less inflammatory cell infiltration and preserved muscular architecture. These data suggest that the NO-np may be an effective addition to our armament for deep soft tissue infections.

Original languageEnglish (US)
Pages (from-to)62-67
Number of pages6
Issue number1
StatePublished - 2012


  • MRSA
  • Nanotechnology
  • Nitric oxide
  • Pyomyositis

ASJC Scopus subject areas

  • Parasitology
  • Microbiology
  • Immunology
  • Microbiology (medical)
  • Infectious Diseases


Dive into the research topics of 'Nitric oxide nanoparticles: Pre-clinical utility as a therapeutic for intramuscular abscesses'. Together they form a unique fingerprint.

Cite this